ELI LILLY AND COMPANY Available-for-sale Securities, Gross Realized Losses
ELI LILLY AND COMPANY (LLY) reported Available-for-sale Securities, Gross Realized Losses of $5.80 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-20.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses · last filed 2018-11-06
- ELI LILLY AND COMPANY available-for-sale securities, gross realized losses for the quarter ending 2017-12-31 was $2.60M, a 10.34% decline year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized losses for the quarter ending 2017-09-30 was $800.00K, a 38.46% decline year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized losses for the quarter ending 2017-06-30 was $1.10M, a 64.52% decline year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized losses for the quarter ending 2017-03-31 was $1.30M, a 82.19% decline year-over-year.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized losses for fiscal 2017 was $5.80M, a 60.27% decline from fiscal 2016.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized losses for fiscal 2016 was $14.60M, a 41.75% increase from fiscal 2015.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized losses for fiscal 2015 was $10.30M, a 64.97% decline from fiscal 2014.
- ELI LILLY AND COMPANY available-for-sale securities, gross realized losses for fiscal 2014 was $29.40M, a 90.91% increase from fiscal 2013.
| Period end | Available-for-sale Securities, Gross Realized Losses 3 month | Available-for-sale Securities, Gross Realized Losses 6 month | Available-for-sale Securities, Gross Realized Losses 9 month | Available-for-sale Securities, Gross Realized Losses 12 month |
|---|---|---|---|---|
| 2017-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $3.40M derived: sum of 2 quarters · filed 2018-11-06 | $4.50M derived: sum of 3 quarters · filed 2018-11-06 | $5.80M 10-K · filed 2018-02-20 |
| 2017-09-30 | $800.00K 10-Q · filed 2018-11-06 | $1.90M derived: sum of 2 quarters · filed 2018-11-06 | $3.20M 10-Q · filed 2018-11-06 | $6.10M derived: sum of 4 quarters · filed 2018-11-06 |
| 2017-06-30 | $1.10M 10-Q · filed 2018-07-25 | $2.40M 10-Q · filed 2018-07-25 | $5.30M derived: sum of 3 quarters · filed 2018-07-25 | $6.60M derived: sum of 4 quarters · filed 2018-07-25 |
| 2017-03-31 | $1.30M 10-Q · filed 2018-04-27 | $4.20M derived: sum of 2 quarters · filed 2018-04-27 | $5.50M derived: sum of 3 quarters · filed 2018-04-27 | $8.60M derived: sum of 4 quarters · filed 2018-04-27 |
| 2016-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $4.20M derived: sum of 2 quarters · filed 2018-02-20 | $7.30M derived: sum of 3 quarters · filed 2018-02-20 | $14.60M 10-K · filed 2018-02-20 |
| 2016-09-30 | $1.30M 10-Q · filed 2017-10-27 | $4.40M derived: sum of 2 quarters · filed 2017-10-27 | $11.70M 10-Q · filed 2017-10-27 | $18.10M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-06-30 | $3.10M 10-Q · filed 2017-07-28 | $10.40M 10-Q · filed 2017-07-28 | $16.80M derived: sum of 3 quarters · filed 2018-02-20 | $18.30M derived: sum of 4 quarters · filed 2018-02-20 |
| 2016-03-31 | $7.30M 10-Q · filed 2017-05-01 | $13.70M derived: sum of 2 quarters · filed 2018-02-20 | $15.20M derived: sum of 3 quarters · filed 2018-02-20 | $16.90M derived: sum of 4 quarters · filed 2018-02-20 |
| 2015-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $7.90M derived: sum of 2 quarters · filed 2018-02-20 | $9.60M derived: sum of 3 quarters · filed 2018-02-20 | $10.30M 10-K · filed 2018-02-20 |
| 2015-09-30 | $1.50M 10-Q · filed 2016-10-28 | $3.20M derived: sum of 2 quarters · filed 2016-10-28 | $3.90M 10-Q · filed 2016-10-28 | $17.10M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | $1.70M 10-Q · filed 2016-07-28 | $2.40M 10-Q · filed 2016-07-28 | $15.60M derived: sum of 3 quarters · filed 2017-02-21 | $16.70M derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $700.00K 10-Q · filed 2016-04-29 | $13.90M derived: sum of 2 quarters · filed 2017-02-21 | $15.00M derived: sum of 3 quarters · filed 2017-02-21 | $26.10M derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $14.30M derived: sum of 2 quarters · filed 2017-02-21 | $25.40M derived: sum of 3 quarters · filed 2017-02-21 | $29.40M 10-K · filed 2017-02-21 |
| 2014-09-30 | $1.10M 10-Q · filed 2015-10-30 | $12.20M derived: sum of 2 quarters · filed 2015-10-30 | $16.20M 10-Q · filed 2015-10-30 | $19.50M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | $11.10M 10-Q · filed 2015-07-30 | $15.10M 10-Q · filed 2015-07-30 | $18.40M derived: sum of 3 quarters · filed 2016-02-19 | $22.60M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-03-31 | $4.00M 10-Q · filed 2015-04-30 | $7.30M derived: sum of 2 quarters · filed 2016-02-19 | $11.50M derived: sum of 3 quarters · filed 2016-02-19 | $16.90M derived: sum of 4 quarters · filed 2016-02-19 |
| 2013-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $7.50M derived: sum of 2 quarters · filed 2016-02-19 | $12.90M derived: sum of 3 quarters · filed 2016-02-19 | $15.40M 10-K · filed 2016-02-19 |
| 2013-09-30 | $4.20M 10-Q · filed 2014-10-29 | $9.60M derived: sum of 2 quarters · filed 2014-10-29 | $12.10M 10-Q · filed 2014-10-29 | $15.60M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-06-30 | $5.40M 10-Q · filed 2014-07-28 | $7.90M 10-Q · filed 2014-07-28 | $11.40M derived: sum of 3 quarters · filed 2015-02-19 | $13.60M derived: sum of 4 quarters · filed 2015-02-19 |
| 2013-03-31 | $2.50M 10-Q · filed 2014-04-28 | $6.00M derived: sum of 2 quarters · filed 2015-02-19 | $8.20M derived: sum of 3 quarters · filed 2015-02-19 | $10.70M derived: sum of 4 quarters · filed 2015-02-19 |
| 2012-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $5.70M derived: sum of 2 quarters · filed 2015-02-19 | $8.20M derived: sum of 3 quarters · filed 2015-02-19 | $10.90M 10-K · filed 2015-02-19 |
| 2012-09-30 | $2.20M 10-Q · filed 2013-10-30 | $4.70M derived: sum of 2 quarters · filed 2013-10-30 | $7.40M 10-Q · filed 2013-10-30 | $9.70M derived: sum of 4 quarters · filed 2014-02-19 |
| 2012-06-30 | $2.50M 10-Q · filed 2013-07-26 | $5.20M 10-Q · filed 2013-07-26 | $7.50M derived: sum of 3 quarters · filed 2014-02-19 | $10.00M derived: sum of 4 quarters · filed 2014-02-19 |
| 2012-03-31 | $2.70M 10-Q · filed 2013-04-26 | $5.00M derived: sum of 2 quarters · filed 2014-02-19 | $7.50M derived: sum of 3 quarters · filed 2014-02-19 | $9.10M derived: sum of 4 quarters · filed 2014-02-19 |
| 2011-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $4.80M derived: sum of 2 quarters · filed 2014-02-19 | $6.40M derived: sum of 3 quarters · filed 2014-02-19 | $9.90M 10-K · filed 2014-02-19 |
| 2011-09-30 | $2.50M 10-Q · filed 2012-10-26 | $4.10M derived: sum of 2 quarters · filed 2012-10-26 | $7.60M 10-Q · filed 2012-10-26 | $8.50M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $1.60M 10-Q · filed 2012-07-27 | $5.10M 10-Q · filed 2012-07-27 | $6.00M derived: sum of 3 quarters · filed 2013-02-21 | $7.60M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | $3.50M 10-Q · filed 2012-04-30 | $4.40M derived: sum of 2 quarters · filed 2013-02-21 | $6.00M derived: sum of 3 quarters · filed 2013-02-21 | $6.50M derived: sum of 4 quarters · filed 2013-02-21 |
| 2010-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $2.50M derived: sum of 2 quarters · filed 2013-02-21 | $3.00M derived: sum of 3 quarters · filed 2013-02-21 | $4.80M 10-K · filed 2013-02-21 |
| 2010-09-30 | $1.60M 10-Q · filed 2011-10-28 | $2.10M derived: sum of 2 quarters · filed 2011-10-28 | $3.90M 10-Q · filed 2011-10-28 | $5.20M derived: sum of 4 quarters · filed 2012-02-24 |
| 2010-06-30 | $500.00K 10-Q · filed 2011-07-29 | $2.30M 10-Q · filed 2011-07-29 | $3.60M derived: sum of 3 quarters · filed 2012-02-24 | $8.10M derived: sum of 4 quarters · filed 2012-02-24 |
| 2010-03-31 | $1.80M 10-Q · filed 2011-04-29 | $3.10M derived: sum of 2 quarters · filed 2012-02-24 | $7.60M derived: sum of 3 quarters · filed 2012-02-24 | $7.90M derived: sum of 4 quarters · filed 2012-02-24 |
| 2009-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | $5.80M derived: sum of 2 quarters · filed 2012-02-24 | $6.10M derived: sum of 3 quarters · filed 2012-02-24 | $6.80M 10-K · filed 2012-02-24 |
| 2009-09-30 | $4.50M 10-Q · filed 2010-10-29 | $4.80M derived: sum of 2 quarters · filed 2010-10-29 | $5.50M 10-Q · filed 2010-10-29 | |
| 2009-06-30 | $300.00K 10-Q/A · filed 2010-08-02 | $1.00M 10-Q/A · filed 2010-08-02 | ||
| 2008-12-31 | $8.70M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |